

# **The role of plasmapheresis in snake envenoming: a systematic review**

Hari Prasad<sup>1¶</sup>, Nidhi Kaeley<sup>2\*¶</sup>, Jewel Rani Jose<sup>3¶</sup>, Ajun U N<sup>4&</sup>, Takshak Shankar<sup>5&</sup>, Ajmal Salam<sup>6&</sup>, Krishna Shukla<sup>7&</sup>

1. Senior Resident, Department of Emergency Medicine, All India Institute of Medical Sciences, New Delhi, India, [hariprasad007007007@gmail.com](mailto:hariprasad007007007@gmail.com)
2. Head of Department, Department of Emergency Medicine, All India Institute of Medical Sciences, Rishikesh, India, [nidhi.em@aiimsrishikesh.edu.in](mailto:nidhi.em@aiimsrishikesh.edu.in)
3. Junior Resident, Department of Emergency Medicine, All India Institute of Medical Sciences, Rishikesh, India, [jewka4229@gmail.com](mailto:jewka4229@gmail.com)
4. Senior Research Officer, Department of Psychiatry, National Institute of Mental Health and Neuro Sciences, Bengaluru, India, [ajun563@gmail.com](mailto:ajun563@gmail.com)
5. Senior Resident, Department of Emergency Medicine, All India Institute of Medical Sciences, Rishikesh, India, [takshak.shankar@gmx.com](mailto:takshak.shankar@gmx.com)
6. Senior Resident, Department of Paediatrics, Aster DM Wayanad Institute of Medical Sciences, Wayanad, India, [ajmalwims@gmail.com](mailto:ajmalwims@gmail.com)
7. DrNB Trainee, Department of Critical Care Medicine, Medanta, The Medicity, Gurgaon, India, [krishna.shukla03@gmail.com](mailto:krishna.shukla03@gmail.com)

**Correspondence:** [nidhi.em@aiimsrishikesh.edu.in](mailto:nidhi.em@aiimsrishikesh.edu.in)

**NOTE:** This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

## Abstract

**Background-** Envenoming from numerous sources, such as snakes, scorpions, and spiders, is a major health issue across the world, resulting in millions of cases and tens of thousands of deaths annually. Venom induced symptoms ranges from systemic reactions like nausea and vomiting to localised pain and swelling. One major risk is the development of venom induced consumption coagulopathy (VICC), which might result in significant consequences. Plasmapheresis is being investigated as a possible therapy for severe envenoming.

**Objectives-** We aim to assess the effectiveness and potential advantages of plasmapheresis in snakebite cases, focusing on clinical results. We seek to find if plasmapheresis improves neurological, renal, and hematological dysfunction and impacts secondary outcomes, including patient discharge rates, morbidity, mortality, duration of hospital stay, and the number of plasmapheresis sessions required.

**Methods-** Following PRISMA guidelines, we conducted a systematic search of articles published between 1980 and July 2023 across multiple databases. MeSH terms related to snakebite and plasmapheresis were applied without publication or language type restrictions. Inclusion criteria considered case reports, cross-sectional studies, or case series featuring plasmapheresis in snakebite management. Inclusions were participants aged 18 years or older with confirmed or suspected snakebites, meeting plasmapheresis indications. Exclusions included participants under 18 years, studies reporting only in vitro data, review articles, and redundant reporting. The emphasis was on Emergency Departments or Intensive Care Units.

**Results-** In a review of 147 cases (1980 to July 2023), the most common snake was the hump-nosed viper (*Hypnale hypnale*). Renal, neurological, and hematological dysfunctions improved after plasmapheresis. The mean plasmapheresis sessions were 2.1, and the average hospital stay was 13.13 days.

**Conclusion-** Once the data has been analyzed, the result emphasizes the clinical importance of plasmapheresis in snakebite envenoming. It helps decision-making when standard therapies are insufficient or ineffective, potentially saving lives.

**Keywords-** plasmapheresis, snakebite, snake bite, snakebite envenoming, therapeutic plasma exchange

## Author Summary

Snakebites pose a significant global health threat, causing numerous deaths and serious injuries annually. While antivenom is the primary treatment, it's not always effective or available. This study explores an alternative treatment called plasmapheresis, a method that filters harmful substances from the blood.

We reviewed 147 cases of snake envenoming treated with plasmapheresis between 1980 and 2023. Our findings show that plasmapheresis can improve various complications caused by snake venom, including kidney problems, nerve damage, and blood disorders. On average, patients received about two plasmapheresis treatments and stayed in the hospital for around 13 days.

The study suggests that plasmapheresis could be a valuable option when standard treatments aren't working well enough. It might help save lives in severe cases of snake envenoming. While more research is needed, this review provides important insights for doctors treating snakebite victims, especially in areas where snakebites are common and resources are limited.

## Background

Envenoming causes significant morbidity and mortality; the most common causes are snakes, scorpions, spiders, bugs, and unidentified bites [1]. According to the World Health Organisation (WHO), there are 2.7 million snake bites globally each year, resulting in 81,000 to 138,000 deaths [2]. Snakebite is classified as a category A Neglected Tropical Disease (NTD) by the WHO [3]. Each year, there are over 81,000 occurrences of snakebite envenoming in India, resulting in 11,000 fatalities [4].

Indian Cobra (*Naja Naja*), Russell's Viper (*Daboia russelii*), and Krait (*Bungarus caeruleus*) are among the most harmful and venomous snakes. Examples of local symptoms include painful regional lymphadenopathy, edema, and discomfort at the bite site. Nausea, vomiting, headaches, diaphoresis, stomach discomfort, and diarrhoea are examples of non-specific systemic symptoms. Toxin syndromes such as neurotoxicity, myotoxicity, and VICC can result from systemic envenoming [5]. Some elapid envenomings cause hemostatic and cardiovascular consequences [6].

Acute kidney injury (AKI), VICC, and tissue destruction are all caused by metalloproteinases, phospholipase A2, and snake lectins, in hematotoxic venom. The major toxin-mediated coagulopathy brought on by a hemotoxic snakebite is VICC, which is then followed by venom-induced Thrombotic Microangiopathy (TMA) and Diffuse

Alveolar Hemorrhage (DAH) [7,8]. Russell's viper (*Daboia russelii*) envenoming causes a specific condition known as Capillary Leak Syndrome (CLS) [9]. Drowsiness, visual abnormalities, and respiratory failure are neurotoxicity signs [6]. Rarely, a snakebite can result in Guillain-Barre Syndrome (GBS) and Insulin Autoimmune Syndrome (IAS), which is treatable with plasmapheresis. For AKI, hemotoxic consequences, CLS, hemodialysis, and antsnake venom are used. But for many, plasmapheresis is a last-ditch option. Plasma exchange is an alternate method for removing venom toxins that are difficult to remove using dialysis or hemoperfusion. Venom toxins can be effectively removed from the blood by plasma exchange but not from other fluid compartments. Plasma exchange may help to reduce venom toxins in the blood compartment and may even cause venom toxins to be redistributed and removed from the extravascular region. Kornalik reported the first instance of plasma exchange being utilized to treat snake bite envenoming in 1990. Rasulov and Berdymuradov reported using plasma exchange in 1994 to treat three of 24 patients who had been bitten by snakes and become envenomed. Zengin et al. found plasmapheresis to be an effective intervention in a retrospective study of 37 snakebite patients with complications not resolving with antivenom administration [10]. Herein, we aim to conduct a systematic review to assess the effectiveness of plasmapheresis in snakebite cases and the situations under which it may be beneficial.

## Methods

### Search strategy

PROSPERO (ID: CRD42023459261) was used to register the study protocol. Prior to the start of the systematic review, a protocol was created using PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses). A comprehensive search approach for articles from 1980 to July 2023 was carried out. PubMed, Embase via Elsevier, MEDLINE via Ovid, The Cochrane Library for Cochrane Reviews, Scopus, Web of Science, and Google Scholar were searched with the MeSH terms 'bite' or 'snakebite' or 'envenomation' or 'snakebite envenoming' and 'plasmapheresis' or 'therapeutic plasma exchange.' Additionally, we contacted the research authors for any missing data, manually checked the reference lists of the included studies, and utilised a database's similar articles function.

### Study selection and screening

HP, NK, and JJ independently screened search results for eligibility. For articles eligible after screening, full texts were retrieved by HP, NK, and JJ, which HP, JJ, NK, AU, TS, AS and KS reviewed. HP and JJ screen the citation search. Discrepancies were resolved by consensus. The selection process was done as in Fig. 1 [11].




Fig. 1- PRISMA above shows the flow of patients.

## Eligibility Criteria

This review aimed to find, assess, and synthesize all cross-sectional studies, case reports, or case series that used plasmapheresis for snakebite along with conventional Anti Snake Venom (ASV), atropine-neostigmine, calcium gluconate or hemodialysis. Only human cases aged more than 18 years, suspected or confirmed snakebites or those who fulfill indications of plasmapheresis were included in the review. We excluded Human cases under 18 years, studies reporting in vitro data only, review articles, or those with complete reporting overlap. The study was set in an Emergency Department or Intensive Care Unit as patients with complications mostly come here.

## Data extraction

HP and JJ were the authors who extracted the data. Each included study provided the following data regarding study characteristics and outcomes:

- Study types: observational studies
- The study's methods included: Authors of the study, year, and study design
- The intervention(s) of interest: kind, frequency, and comparator(s) used: normal care
- Age, gender, and the outcomes listed above were characteristics of the participants' studies.

## Assessment of the Risk of Bias

The risk of bias for each research was independently assessed by five review authors (NK, AN, TS, HP, JJ, AS and KS) using the Murad MH, Sultan S, Haffar S, Bazerbachi F. Methodological quality and synthesis of case series and case reports. BMJ Evid-Based Med. 2018;23(2): 60–3 [12].

## Outcome

The study's primary outcomes were 'improvement in renal dysfunction' defined as patients becoming KDIGO 1 at discharge, 'improvement in neurological dysfunction' defined as Guillain Barre Syndrome disability score 0-2 at discharge, or 'improvement in hematological dysfunction' described as hemoglobin and platelets returning to age-appropriate normal limits without schistocytes following plasmapheresis done for snakebite. The secondary outcomes were discharge or death, morbidity (KDIGO 2 or 3, Guillain Barre Syndrome disability score 3-5, no return to age-appropriate limits for hemoglobin and platelets), hospital stay duration, and number of plasmapheresis. This helps to determine the role of plasmapheresis and its effectiveness in the snakebite.

## Analysis

The mean and standard deviation for normal distributions, the median (interquartile range) for non-normal distributions of numerical variables, and percentages and proportions for categorical variables were the ways in which descriptive statistics were stated. The data was analysed using SPSS 23.0.

## Results

This systematic review includes 147 patients from 40 studies carried out between 1980 and July 2023. The population's average age was  $49.9 \pm 14$  years, with 59.9% of patients being male.

**Main results:** Regarding the types of snake bites, 77 cases involved unidentified snake species, while the hump-nosed viper (*Hypnale hypnale*, one of which is *Hypnale zara*) accounted for most known snakebites (42). This was followed by eight each for Russell's viper (*Daboia russelii*) and saw-scaled viper (five *Echis carinatus*, one *Echis pyramidum*, one *Echis coloratus*, one *Echis sochureki*), three pit vipers (two *Bothrops asper*, one *Crotalus cerastes*), and other viper species (*Proatheris superciliaris*, *Cerastes cerastes*) accounting for two. Additionally, there were three krait bites (one *Bungarus caeruleus*, one *Bungarus multicinctus*, one *Bungarus candidus*), one sea snake bite (*Hydrophis platurus*), one Australian brown snake bite (*Pseudonaja nuchalis*), one taipan bite (*Oxyuranus scutellatus*), and one Colubridae snake bite (*Notechis scutatus*).

A summary table showing study included, type of snake, indication for plasmapheresis and geographical location of snakebite are shown in Table 1.

**Table 1:** Summary Table

| Sl.No | Author               | Study                             | Snake                  | Indication | Geographical Location |
|-------|----------------------|-----------------------------------|------------------------|------------|-----------------------|
| 1.    | Yildirim et al. [13] | Retrospective descriptive study   | N/A                    | VICC       | Turkey                |
| 2.    | Arora et al. [14]    | Case report                       | <i>Daboia russelii</i> | TMA        | India                 |
| 3.    | Mohan et al. [15]    | Case report                       | <i>Daboia russelii</i> | TMA        | India                 |
| 4.    | Zengin et al. [10]   | Retrospective observational study | N/A                    | VICC       | Turkey                |
| 5.    | Berber et al. [16]   | Observational study               | N/A                    | VICC       | Turkey                |

|     |                         |                                   |                                 |      |                 |
|-----|-------------------------|-----------------------------------|---------------------------------|------|-----------------|
| 6.  | Dineshkumar et al. [17] | Case report                       | <i>Daboia russelii</i>          | TMA  | India           |
| 7.  | Erkurt et al. [18]      | Retrospective observational study | N/A                             | VICC | Turkey          |
| 8.  | Rathnayaka et al. [19]  | Prospective observational study   | <i>Hypnale hypnale</i>          | TMA  | Srilanka        |
| 9.  | Isbister et al. [20]    | prospective observational study   | <i>Pseudonaja nuchalis</i>      | TMA  | Australia       |
| 10. | Rahmani et al. [21]     | Case series                       | <i>Echis coloratus</i>          | TMA  | Israel          |
| 11. | Obeidat et al. [22]     | Case Report                       | <i>Echis carinatus</i>          | TMA  | Jordan          |
| 12. | Keyler et al. [23]      | Case Report                       | <i>Proatheris superciliaris</i> | TMA  | USA             |
| 13. | Kornalik et al. [24]    | Case Report                       | <i>Bothrops asper</i>           | VICC | Czechoslovakia. |
| 14. | Valenta et al. [25]     | Case Report                       | <i>Echis pyramidum</i>          | TMA  | Czech Republic  |
| 15. | Sampley et al. [26]     | Case Report                       | N/A                             | DAH  | India           |
| 16. | Grace et al. [27]       | Case Report                       | N/A                             | CLS  | India           |
| 17. | Hameed et al. [28]      | Case Report                       | <i>Hydrophis platurus</i>       | GBS  | Pakistan        |
| 18. | Cobcroft et al. [29]    | Case Report                       | <i>Oxyuranus scutellatus</i>    | TMA  | Australia       |
| 19. | Chuang et al. [30]      | Case Report                       | <i>Bungarus multicinctus</i>    | GBS  | Taiwan          |



|     |                            |                                 |                           |     |          |
|-----|----------------------------|---------------------------------|---------------------------|-----|----------|
| 20. | Akhilesh Kumar et al. [8]  | Case Report                     | <i>Echis sochureki</i>    | DAH | India    |
| 21. | Withana et al. [31]        | Case Report                     | <i>Hypnale hypnale</i>    | TMA | Srilanka |
| 22. | Mitrakrishnan et al. [32]  | Case Report                     | <i>Hypnale hypnale</i>    | TMA | Srilanka |
| 23. | Rathnayaka et al. [33]     | Case Series                     | <i>Daboia russelii</i>    | TMA | Srilanka |
| 24. | Srivastava et al. [34]     | Case Report                     | N/A                       | GBS | India    |
| 25. | Reddy et al. [35]          | Case Report                     | <i>Daboia russelii</i>    | TMA | India    |
| 26. | Cañas et al. [36]          | Case Report                     | <i>Bothrops asper</i>     | TMA | Colombia |
| 27. | Rathnayaka et al. [37]     | Case report                     | Hypnale zara              | TMA | Srilanka |
| 28. | Godavari et al. [38]       | Case Report                     | N/A                       | TMA | India    |
| 29. | Murthy et al. [39]         | Case Report                     | N/A                       | TMA | India    |
| 30. | Wijewickrama et al. [40]   | Prospective observational study | <i>Hypnale hypnale</i>    | TMA | Srilanka |
| 31. | Janarthanam et al. [41]    | Case Report                     | <i>Crotalus cerastes</i>  | GBS | India    |
| 32. | Senthilkumaran et al. [42] | Case Report                     | <i>Bungarus caeruleus</i> | IAS | India    |
| 33. | Priyankara et al. [43]     | Case Report                     | <i>Daboia russelii</i>    | TMA | Srilanka |
| 34. | Laothong et al. [44]       | Case Series                     | <i>Bungarus candidus</i>  | GBS | Thailand |

|     |                        |             |                          |                |           |
|-----|------------------------|-------------|--------------------------|----------------|-----------|
| 35. | Herath et al. [45]     | case series | <i>Hypnale hypnale</i>   | TMA            | Srilanka  |
| 36. | Bava et al. [46]       | Case series | <i>Echis carinatus</i>   | DAH, VICC, TMA | India     |
| 37. | Elmoqaddem et al. [47] | Case report | <i>Cerastes cerastes</i> | VICC           | Morocco   |
| 38. | Casamento et al. [48]  | Case Series | <i>Notechis scutatus</i> | TMA            | Australia |

154 CLS, Capillary Leak Syndrome; DAH, Diffuse Alveolar Hemorrhage; GBS, Guillain-Barre Syndrome; IAS,  
 155 Insulin Autoimmune Syndrome; TMA, Thrombotic Microangiopathy; USA, United States of America; VICC,  
 156 venom-induced consumption coagulopathy

157 Among the indications for plasmapheresis, the majority (51%) was performed for VICC, while 42.2% of cases  
 158 were for TMA and 3.4% for GBS. Three cases involved DAH, and one each involved CLS and IAS, all of which  
 159 underwent plasmapheresis.

| Sl.No | Author               | Number of patients * | Age or Range | Sex (Number of Male/Female) | Renal dysfunction present or not. If yes improved or deteriorated following TPE | Neurological dysfunction present or not. If yes improved or deteriorated following TPE | Blood dysfunction present or not. If yes improved or deteriorated following TPE |
|-------|----------------------|----------------------|--------------|-----------------------------|---|--|---|
| 1.    | Yildirim et al. [13] | 13                   | 21-75        | 9/4                         | -   | -  | Yes, Improved   |
| 2.    | Arora et al. [14]    | 1                    | 44           | 1/-                         | Yes, Improved   | -  | Yes, Improved   |
| 3.    | Mohan et al. [15]    | 1                    | 70           | -/1                         | Yes, Improved   | -  | Yes, Improved   |

|     |                         |    |       |       |   |    |                                       |
|-----|-------------------------|----|-------|-------|---|----|---------------------------------------|
| 4.  | Zengin et al. [10]      | 33 | 20-79 | 19/14 | Yes, Improved                                     | -  | Yes, Improved                         |
| 5.  | Berber et al. [16]      | 20 | 49.55 | 17/3  | Yes, 19 improved 1 Death                          | -  | Yes, 19 improved 1 Death              |
| 6.  | Dineshkumar et al. [17] | 1  | 56    | 1/-   | Yes/ Not improved-ESRD                            | -  | Yes/ Improved                         |
| 7.  | Erkurt et al. [18]      | 5  | 21-80 | 1/4   | Yes, Improved                                     | -- | Yes, Improved                         |
| 8.  | Rathnayaka et al. [19]  | 21 | 29-70 | 14/7  | Yes/ 16 improved 5 Not improved (1 Death, 4 ESRD) | -  | Yes/ 20 improved 1 Not improved-Death |
| 9.  | Isbister et al. [20]    | 1  | 42    | 1/-   | Yes, Improved                                     | -  | Yes, Improved                         |
| 10. | Rahmani et al. [21]     | 2  | 39,70 | 2/-   | Yes, Improved                                     | -  | Yes, Improved                         |
| 11. | Obeidat et al. [22]     | 1  | 25    | 1/-   | Yes, Improved                                     | -  | Yes, Improved                         |
| 12. | Keyler et al. [23]      | 1  | 27    | 1/-   | Yes, Improved                                     | -  | Yes, Improved                         |
| 13. | Kornalik et al. [24]    | 1  | 60    | 1/-   | -   | -  | Yes, Improved                         |
| 14. | Valenta et al. [25]     | 1  | 41    | 1/-   | Yes, Improved                                     | -  | Yes, Improved                         |
| 15. | Sampley et al. [26] €   | 1  | 36    | 1/-   | Yes, Improved                                     | -  | Yes, Improved                         |

|     |                                   |   |       |     |                                |                                       |                                |
|-----|-----------------------------------|---|-------|-----|--------------------------------|---------------------------------------|--------------------------------|
| 16. | Grace et al. [27]<br>§            | 1 | 28    | 1/- | Yes,<br>Improved               | -                                     | Yes,<br>Improved               |
| 17. | Hameed et al.<br>[28]             | 1 | 21    | 1/- | -                              | Yes/ Not<br>improved-<br>Neurodeficit | -                              |
| 18. | Cobcroft et al.<br>[29]           | 1 | 33    | 1/- | Yes/ Not<br>improved-<br>Death | -                                     | Yes/ Not<br>improved-<br>Death |
| 19. | Chuang et al.<br>[30]             | 1 | 36    | 1/- | -                              | Yes/<br>Improved                      | -                              |
| 20. | Akhilesh<br>Kumar et al. [8]<br>Ω | 1 | 40    | 1/- | -                              | -                                     | Yes,<br>Improved               |
| 21. | Withana et al.<br>[31]            | 1 | 55    | -/1 | Yes,<br>Improved               | -                                     | Yes,<br>Improved               |
| 22. | Mitrakrishnan<br>et al. [32]      | 1 | 70    | 1/- | Yes,<br>Improved               | -                                     | Yes,<br>Improved               |
| 23. | Rathnayaka et<br>al. [33]         | 1 | 66    | -/1 | Yes, Not<br>Improved-<br>ESRD  | -                                     | Yes,<br>Improved               |
| 24. | Srivastava et al.<br>[34]         | 1 | 40    | 1/- | -                              | Yes,<br>Improved                      | -                              |
| 25. | Reddy et al.<br>[35]              | 1 | 55    | -/1 | Yes,<br>Improved               | -                                     | Yes,<br>Improved               |
| 26. | Cañas et al. [36]                 | 1 | 57    | 1/- | Yes,<br>Improved               | -                                     | Yes,<br>Improved               |
| 27. | Rathnayaka et<br>al. [37]         | 3 | 55-74 | 2/1 | Yes,<br>Improved               | -                                     | Yes,<br>Improved               |
| 28. | Godavari et al.<br>[38]           | 2 | 30,49 | 1/1 | Yes,<br>Improved               | -                                     | Yes,<br>Improved               |

|     |                              |   |       |     |  |                  |                                       |
|-----|------------------------------|---|-------|-----|--|------------------|---------------------------------------|
| 29. | Murthy et al. [39]           | 1 | 51    | 1/- | Yes, Improved                                    | -                | Yes, Improved                         |
| 30. | Wijewickrama et al. [40]     | 9 | 39-59 | 3/6 | Yes, Improved                                    | -                | Yes, Improved                         |
| 31. | Janarthanam et al. [41]      | 1 | 29    | -/1 | -  | Yes, Improved    | -                                     |
| 32. | Senthilkumaran et al. [42] # | 1 | 54    | -/1 | -  | -                | -                                     |
| 33. | Priyankara et al. [43]       | 1 | 70    | -/1 | Yes, Improved                                    | -                | Yes, Improved                         |
| 34. | Laothong et al. [44]         | 1 | 35    | 1/- | -  | Yes, Improved \$ | -                                     |
| 35. | Herath et al. [45]           | 7 | 44-76 | 3/4 | Yes/ 3 Improved 4 Not improved (2 Death, 2 ESRD) | -                | Yes, 5 Improved, 2 Not improved-Death |
| 36. | Bava et al. [46] ¥           | 3 | 40-50 | 2/1 | Yes, 2 Improved                                  | -                | Yes, 2 Improved                       |
| 37. | Elmoqaddem et al. [47]       | 1 | 43    | 1/- | Yes, Improved                                    | -                | -                                     |
| 38. | Casamento et al. [48]        | 1 | 55    | -/1 | Yes, Improved                                    | -                | Yes, Improved                         |

160 ESRD End Stage Renal Disease

161 \* Number of patients with snakebite as per inclusion criteria of the review

162 #- Patient with Insulin Autoimmune syndrome post snakebite improved following TPE

163 € This patient with DAH post snakebite had concomitant renal and blood dysfunction too all 3 improved following  
164 TPE

165 § This patient with CLS post snakebite had concomitant renal and blood dysfunction too all 3 improved following  
166 TPE

167 Ω This patient with DAH post snakebite had concomitant blood dysfunction both of which improved following  
168 TPE

169 \$ Improved but have persistent autonomic dysfunction

170 ¥ Patient with DAH post snakebite improved following TPE

171

172 Of the 124 patients who developed renal dysfunction, 112 showed improvement after plasmapheresis. Five of the  
173 eight patients who developed neurological dysfunction showed improvement after plasmapheresis. Of the 136  
174 patients who developed hematological derangements, 124 improved after plasmapheresis. Furthermore, one  
175 patient with IAS who developed autonomic dysfunction also improved after plasmapheresis.

176 From the available data, 90.5% of patients were discharged from the hospital, while nine patients succumbed to  
177 death. Among the patients, 86.4% did not develop residual clinical effects on discharge (no morbidity), 7.5%  
178 developed end-stage renal disease, two developed residual limb weakness, and one developed autoimmune  
179 dysfunction. Relation of indication for plasmapheresis and duration of hospital stay is shown in Fig. 2.

180

181 Fig. 2: Mean duration of hospital stay and indications of plasmapheresis

182




Fig. 2: Bar diagram showing mean duration of hospital stay with plasmapheresis indications

CLS, Capillary Leak Syndrome; DAH, Diffuse Alveolar Hemorrhage; GBS, Guillain-Barre Syndrome; IAS, Insulin Autoimmune Syndrome; TMA, Thrombotic Microangiopathy; VICC, venom-induced consumption coagulopathy

The duration of hospital stay showed high variability, ranging from 1 to 65 days, with a mean of 13.1 days. The number of plasmapheresis sessions ranged from 1 to 14, with a median of 2 and an interquartile range (IQR) of (1,4).

## Discussion

Snakebites are an occupational danger, with the majority of bites occurring on farms when working barefoot or wandering through the fields at night. The four families of venomous snakes are the Elapidae, Viperidae, Hydrophidae, and Colubridae. Elapid venom's most prevalent clinical effects are neurotoxic, whereas viper venom causes vascular toxicity and nephropathy, and Hydrophiinae or sea snake venom is myotoxic [49].

AKI is a common complication of snakebite and a significant cause of death and morbidity. 75% of instances of AKI in this situation are caused by acute tubular necrosis (ATN), while 5–15% of cases are caused by acute interstitial nephritis (AIN) [38]. The prevalence of AKI following Russell's viper (*Daboia russelii*) and *Echis carinatus* bites ranges from 13 to 32%. Pathogenesis of AKI in snake envenoming involves hemolysis, rhabdomyolysis, DIC, sepsis, hemodynamic abnormalities, and cell damage caused by the production of proinflammatory cytokines and vasoactive mediators [17,38].

## Venom induced consumption coagulopathy (VICC)

The hemotoxic venom activates coagulation pathways leading to VICC without thrombocytopenia and is characterized by severe bleeding without visible fibrin deposition, microvascular thrombosis, or end-organ failure, which results from snake toxins activating the coagulation pathway. This results in a prolonged prothrombin time, increased fibrinogen consumption, and elevated D-dimer levels, all overlapping with DIC. TMA appears in a subset of individuals with or without VICC whom a snake bite has envenoming. While the coagulopathy in VICC resolves rapidly, the triad of TMA (AKI, thrombocytopenia, and microangiopathic hemolytic anemia) persists for longer. Most cases of TMA following snake envenoming have been documented in Sri Lanka and Australia; very few cases have been reported in India. The proposed mechanism is that venom or its vascular endothelial toxins may function as factors related to VEGF or von Willebrand factor (vWF) activators and cause endothelium damage to initiate TMA. The role of ADAMTS-13, a VWF-cleaving protease, in snake bites requires more investigation [14,17].

The symptoms of TMA often begin 1-3 days after the bite and last longer than those of VICC, which typically resolves after 12–24 h of antivenom infusion. According to Bull et al., either the presence of intravascular fibrin or endothelial injury may predispose to fibrin deposition [50]. These data show that TMA may not always be the same as VICC. Certain species, including *B. jararaca*, induce TMA by up-regulating and activating the genes that produce inflammatory mediators such matrix metalloproteinase (MMP)-10, IL-8, VCAM-1, and E-selectin. Jararhagin, a hemorrhagic metalloproteinase discovered from *B. jararaca* venom, may cause a systemic proinflammatory response [51,52].

The ecarin enzyme converts prothrombin directly into meizothrombin and is primarily responsible for the pathophysiology of envenoming in members of the *Echis* genus. Disintegrins, including echistatin, ocellatin, and pyramidin, are other venom components that prevent platelet aggregation [53]. Hemorrhaging-like substances exacerbate prothrombotic activation and the production of fibrin deposits and lead to afibrinogenemia [25].

TPE for VICC was done in 51.1% of the study's subjects, with 98.6% having their blood dysfunction improved.

## **Thrombotic Micro Angiopathy (TMA)**

TMA is a pathological diagnosis and is associated with acute kidney injury (AKI), Microangiopathic Hemolytic Anemia (MAHA) and thrombocytopenia. Thrombotic thrombocytopenic purpura (TTP) and haemolytic uraemic syndrome (HUS) are the prototype diseases associated with TMA. The first is thrombotic thrombocytopenic purpura (TTP), which was discovered in 1925 in a 16-year-old female patient by Eli Moschcowitz. The second condition is hemolytic uremic syndrome (HUS), which was discovered by Gasser in 1955 in five newborns who



had renal failure, thrombocytopenia, and hemolytic anaemia as a result of a diarrheal sickness [54,55]. Bite-related HUS or HUS-like alterations in Western Australia have been linked to gwadar (*Demansia nuchalis nuchalis*), dugite (*Demansia nuchalis affinis*), and Russell's viper (*Daboia russelii*) bites in India. The difference between HUS and TTP is a little arbitrary because there is much overlap between the two, and it would be preferable to think of them as a continuum of a related disease process [29].

TMA is not included in the categories of complement factor dysregulation or ADAMTS 13 deficiency. The primary cause of TMA pathogenesis, according to the study, is endothelial cell damage or dysfunction, which exposes thrombogenic components to coagulation factors and platelets. Endothelial damage occurs as a result of uncontrolled inflammation and/or genetic or acquired abnormalities of complement or hemostasis mediators, as shown in TMA. TPE may be considered as a therapy option for such people if TMA is shown to be the consequence of snake envenoming [15]. TPE for TMA was done in 42.2 % of the study's subjects, with 77.76 % having their renal dysfunction improved and 92.5% have their blood dysfunction improved.

### **Guillain Barre Syndrome (GBS)**

The first instance of GBS associated with a snakebite was reported by Chuang et al. in 1996. Four weeks after being bitten by a *Bungarus multicinctus*, sensorimotor axonal-type polyneuropathy was identified by EMG/NCS. After therapy (plasmapheresis and 500 mg/day of methylprednisolone for five days), the patient's condition improved [30]. In 2010, Srivastava et al. reported that EMG/NCS revealed motor and sensory neuropathy five weeks after the bite, indicating demyelination with subsequent axonal degradation. Plasmapheresis aided the patient's recovery [34]. Neil et al. (2011) described a patient who experienced paraesthesia and quadriparesis 12 days after being bitten by a *Vipera aspis* snake. The researchers discovered molecular similarity between venom proteins and neuronal GM2 gangliosides, hypothesising an immunological explanation rather than direct venom toxicity for this relationship [28,56]. TPE for GBS was performed on 3.4% of the study's individuals, with four of them having neurological dysfunction improved and one having neurodeficit. One of those who improved had persisting autonomic dysfunction.

### **Diffuse Alveolar Hemorrhage (DAH)**

DAH is a potentially fatal pulmonary complication in various conditions characterized by hypoxemia caused by alveolar infiltrates, which leads to alveolar hemorrhage and necessitates rapid treatment and lifesaving measures. DAH's causes can be immunological and non-immune. The pathophysiology includes widespread alveolar destruction, alveolar hemorrhage, and antibody-mediated pulmonary capillaritis. Direct venom action

and/or an insult mediated by an antibody might account for the delayed DAH by causing widespread alveolar injury. Sampley et al. described DAH in viper envenoming during the first week, with a normal coagulation profile controlled with methylprednisolone and plasmapheresis. The effective use of plasmapheresis and methylprednisolone in DAH on day three following a hump-nosed pit viper (*Hypnale hypnale*) bite, including VICC and thrombotic microangiopathy, was described by Srirangan et al. Therefore, plasma exchange has a limited role in the treatment of snakebite despite evidence supporting its use in thrombotic microangiopathy [8,26]. TPE was performed on three individuals with DAH, two of whom had concurrent blood malfunction and one of whom had concurrent renal impairment. All of which improved after TPE.

### **Capillary Leak Syndrome (CLS)**

Dr. Bayard Clarkson discovered CLS, also known as Clarkson's illness, in 1960. Its defining features are hemoconcentration, hypotension, generalized edema, and hypoalbuminemia without albuminuria [57]. Capillary hyperpermeability and plasma extravasation are the essential mechanisms. CLS can develop as a primary (idiopathic) disorder or a complication of other illnesses. Snake venom contains toxins and enzymes that promote capillary permeability and cause plasma to escape from the intravascular region. The clinical appearance of CLS goes through three stages. First, a prodromal phase of irritation, myalgia, thirst, and syncope. Second, the capillary leakage phase is characterized by intravascular fluid extravasation. Third, complication phase-renal failure is a frequent complication [27]. There are no recognized diagnostic criteria, but with minor revisions, the Thomas and Kumar criteria can be used for diagnosis.

Treatment includes theophylline, leukotriene antagonists, terbutaline, plasmapheresis, corticosteroids, and intravenous immunoglobulin (IG), disease-modifying therapy medications. The outlook for CLS is still quite bad because there is no established treatment. We hypothesized that the patient's favorable result may have been influenced by early CLS detection, timely plasmapheresis implementation, and the use of fresh frozen plasma [58]. TPE was done for one patient with CLS post snakebite who had concomitant renal and blood dysfunction too all of which improved following treatment.

### **Insulin Autoimmune Syndrome (IAS)**

In the early 1970s, Hirata and colleagues described Insulin Autoimmune Syndrome (IAS). Postprandial hypoglycemia, increased insulin levels, and detectable insulin antibodies are all indications of IAS. These antibodies, most often IgG, are considered to bind to circulating insulin and inhibit its interaction with its receptor.

There have been a few accounts of a snakebite-inducing IAS. Many biomolecules in snake venom have the potential to be antigenic. Common krait's (*Bungarus caeruleus*) venom may contain a compound with structural resemblance to endogenous insulin, leading to the production of antibodies against its epitope, or venoms could include substances that reduce disulfide and cause the production of monomers. The existence of the HLA-DRB1\*0406 allele has been linked to the onset of IAS. Dextrose infusions, corticosteroids, somatostatin, diazoxide, azathioprine, rituximab, metformin, dietary changes, and plasmapheresis have all been used to treat IAS. Plasmapheresis rapidly decreased the patient's autoantibody level and reversed their condition. Therefore, once the diagnosis has been made, particularly for individuals with krait (*Bungarus caeruleus*) envenoming, early usage of plasmapheresis will be beneficial [42]. One patient with Insulin Autoimmune syndrome post snakebite was there in study who improved following TPE

### **Plasmapheresis**

Plasma exchange is an alternate method for removing venom toxins that are difficult to remove using dialysis or hemoperfusion. Venom toxins can be effectively removed from the blood by plasma exchange but not from other fluid compartments. Plasma exchange may help to reduce venom toxins in the blood compartment and may even cause venom toxins to be redistributed and removed from the extravascular region. Kornalik reported the first instance of plasma exchange being utilized to treat snake bite envenoming in 1990. Rasulov and Berdymuradov reported using plasma exchange in 1994 to treat three of 24 patients who had been bitten by snakes and become envenomed. Zengin et al. found plasmapheresis to be an effective intervention in a retrospective study of 37 snakebite patients with complications not resolving with antivenom administration [10].

Plasmapheresis has been utilized to treat TMA caused by snake bites in the absence of antivenom. Plasma exchange therapy should be started before a laboratory test can definitively establish the diagnosis because of the substantial mortality risk associated with TTP. This lack of supporting evidence shows that plasma exchange has only a minor role in snakebite envenoming. Therapeutic plasma exchange for snakebite envenoming is classified as Category III, grade 2 C by the American Society for Apheresis (ASFA) (poor recommendation, low-quality or extremely low-quality evidence) [8].

According to the ASFA criteria, acquired TTP is a category I indication for TPE (grade 1A evidence). TPE has two advantages: it eliminates autoantibodies against ADAMTS13 and infuses donor plasma with exogenous

ADAMTS13 enzyme. The ASFA classified (Shiga like Toxin-Producing E.coli) STEC-HUS as category IV. The argument for using TPE in aHUS is that when allogeneic donor plasma is utilized as the replacement fluid for the exchange; this treatment will eliminate the faulty complement proteins and autoantibodies against complement factor H (CFH). According to ASFA recommendations, TPE is a second-line treatment for patients with additional complement mutations (category II, grade 2C) and a first-line treatment for those who have anti-CFH autoantibodies (category I, grade 2C) [23,59].

Other indications for plasmapheresis include Guillain-Barré syndrome, ANCA-associated and Goodpasture glomerulonephritis, chronic demyelinating polyradiculoneuropathy, recurrent focal segmental glomerulosclerosis, hyperviscosity in monoclonal gammopathies, myasthenia gravis, and encephalitis (Category 1). Acute encephalomyelitis, cardiac and stem cell transplantation desensitisation, antiphospholipid syndrome, cryoglobulinemia, cardiomyopathy, Hashimoto encephalopathy, Lambert-Eaton syndrome, multiple sclerosis, and myeloma nephropathy (Category 2) are also included. Category 3 indications include acute liver failure, autoimmune hemolytic anaemia, burn shock, newborn lupus, chronic encephalitis, heparin-induced thrombocytopenia, pancreatitis, refractory thrombocytopenia, paraneoplastic syndromes, sepsis, and vasculitis. Systemic amyloidosis, dermatomyositis/polymyositis, and lupus nephritis are all classified under Category 4 [60].

Contraindications for therapeutic plasmapheresis include lack of central line access or large bore peripheral lines, hemodynamic instability or septicemia, a known allergy to fresh frozen plasma or replacement colloid/albumin, or heparin; relative contraindications include hypocalcemia and angiotensin-converting enzyme (ACE) inhibitor use within the previous 24 hours [61]. Complications of plasmapheresis are hypocalcemia or hypomagnesemia due to citrate anticoagulation, hypotension, flushing, nausea and vomiting, hypothermia, fluid and electrolyte imbalances, transfusion reactions, thrombocytopenia and hypofibrinogenemia causing bleeding diatheses [62]. Plasmapheresis is an effective treatment for a variety of acute and chronic conditions. It may also be used to help prepare for operations and surgeries, as well as to support postoperative recovery and minimise respiration periods. In general, the risks and side effects are minor, with the most prevalent being brief hypotension and associated symptoms [63].

However, antivenom should be administered as soon as feasible, and plasma exchange should be considered as a supplemental therapy strategy for patients with severe envenoming, particularly in managing hematologic issues and limb preservation/salvage techniques. We believe that plasma exchange treatment is advantageous because it

eliminates toxins and inflammatory mediators. If the envenoming from a snake bite cannot be adequately treated using standard methods, plasma exchange may be explored as part of the treatment [10].

So, we propose that plasmapheresis could be used in snakebites in complications such as VICC, TMA, GBS, DAH, CLS, and IAS. Given the rarity of presentation and lack of evidence, plasma exchange could be a lifesaving intervention in some circumstances. The effectiveness of plasma exchange in treating snake bite envenoming should be clarified by conducting extensive randomized controlled trials.

### **Limitations and strengths**

We have included only case series, case reports, and cross-sectional studies as it is challenging to carry out a randomized controlled trial, case-control, or cohort study. The risk of bias was assessed by a nonconventional method using Murad et al. Comparative studies of hemodialysis versus plasmapheresis are required. Plasmapheresis is a costly procedure, and widespread availability is a concern.

The study's strength is that it is one of the first to analyze the role of plasmapheresis in snake bite and to list the indications when plasmapheresis may be used in snakebites.

### **Conclusion**

Snakebites are serious occupational hazards particularly affecting people in agricultural contexts. Various snake venoms have diverse toxicological profiles, including neurotoxicity, vascular toxicity, nephropathy, and myotoxicity. Acute kidney damage (AKI) is a common and serious complication of snakebite, usually caused by acute tubular necrosis. Hemotoxic venoms can cause coagulopathies, resulting in thrombotic microangiopathy (TMA), which is characterised by acute kidney injury, thrombocytopenia, and microangiopathic hemolytic anaemia. Plasma exchange (plasmapheresis) has emerged as a potential therapeutic option for snakebite complications such as TMA, Guillain-Barré syndrome, diffuse alveolar haemorrhage (DAH), and capillary leak syndrome (CLS). Despite limited evidence, plasmapheresis can be life-saving by removing toxins and inflammatory mediators from the circulation. It is especially useful when conventional therapies are insufficient. Randomised controlled trials are required for establishing the effectiveness of plasmapheresis in snakebite envenoming, however its use as an adjuvant treatment shows promise for improving patient outcomes in severe envenoming.

### **Acknowledgements**

374 None

## 375 **Author Contributions**

376 NK had full access to all of the study's data and accepts responsibility for the data's integrity and the correctness  
377 of the data analysis. As co-first authors, HP and JRJ contributed equally.

378 Corresponding author: NK

379 Concept and design: HP, NK, JRJ, AU, TS, AS, KS.

380 Acquisition, analysis, or interpretation of data: HP, JRJ, AU.

381 Drafting of the manuscript: HP, NK, JRJ, AS, AU, TS, KS

382 Critical revision of the manuscript for important intellectual content: HP, JRJ, NK, AS, KS, AU, TS

383 Statistical analysis: AU, HP, JRJ.

384 Administrative, technical, or material support: NK.

385 Supervision: HP, JRJ, NK, AS, KS, TS, AU

## 386 **Funding**

387 None.

## 388 **Availability of data and materials**

389 The datasets generated during and/or analysed during the current study are available from the corresponding  
390 author on reasonable request.

## 391 **Declarations**

392 Ethics approval and consent to participate

393 Not applicable.

## 394 **Consent for publication**

395 Not applicable

## 396 **Competing interests**

397 The authors declare that they have no competing interests.

## 398 Author Information

399 HP, Junior Resident, Department of Emergency Medicine, All India Institute of Medical Sciences, Rishikesh,  
400 India, [hariprasad007007007@gmail.com](mailto:hariprasad007007007@gmail.com)

401 NK, Head of Department, Department of Emergency Medicine, All India Institute of Medical Sciences, Rishikesh,  
402 India, [nidhi.em@aiimsrishikesh.edu.in](mailto:nidhi.em@aiimsrishikesh.edu.in)

403 JRJ, Junior Resident, Department of Emergency Medicine, All India Institute of Medical Sciences, Rishikesh,  
404 India, [jewka4229@gmail.com](mailto:jewka4229@gmail.com)

405 AU, Junior Resident, Department of Community and Family Medicine, All India Institute of Medical Sciences,  
406 Rishikesh, India, [ajun563@gmail.com](mailto:ajun563@gmail.com)

407 TS, Senior Resident, Department of Emergency Medicine, All India Institute of Medical Sciences, Rishikesh,  
408 India, [takshak.shankar@gmx.com](mailto:takshak.shankar@gmx.com)

409 AS, Junior Resident, Department of Paediatrics, All India Institute of Medical Sciences, Rishikesh, India,  
410 [ajmalwims@gmail.com](mailto:ajmalwims@gmail.com)

411 KS, MD, Senior Resident, Department of Emergency Medicine, All India Institute of Medical Sciences,  
412 Rishikesh, India, [krishna.shukla03@gmail.com](mailto:krishna.shukla03@gmail.com)

## 413 References

414 1. White J. Bites and stings from venomous animals: a global overview. Ther Drug Monit. 2000;22(1):65–8.

415 2. World Health Organization. Snakebite envenoming: a strategy for prevention and control [Internet].  
416 Geneva: World Health Organization; 2019 [cited 2023 Aug 18]. 50 p. Available from:  
417 <https://apps.who.int/iris/handle/10665/324838>

418 3. Lancet T. Snake-bite envenoming: a priority neglected tropical disease. The Lancet [Internet]. 2017 Jul  
419 1 [cited 2022 Jul 23];390(10089):2. Available from: [https://www.thelancet.com/journals/lancet/article/PIIS0140-  
420 6736\(17\)31751-8/fulltext](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(17)31751-8/fulltext)

421 4. Kasturiratne A, Wickremasinghe AR, Silva N de, Gunawardena NK, Pathmeswaran A, Premaratna R, et  
422 al. The Global Burden of Snakebite: A Literature Analysis and Modelling Based on Regional Estimates of

- 423 Envenoming and Deaths. PLOS Med [Internet]. 2008 Nov 4 [cited 2023 Aug 18];5(11):e218. Available from:  
424 <https://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.0050218>
- 425 5. Slagboom J, Kool J, Harrison RA, Casewell NR. Haemotoxic snake venoms: their functional activity,  
426 impact on snakebite victims and pharmaceutical promise. Br J Haematol [Internet]. 2017 [cited 2023 Aug  
427 18];177(6):947–59. Available from: <https://onlinelibrary.wiley.com/doi/abs/10.1111/bjh.14591>
- 428 6. Schrire L, Muller GJ, Pantanowitz L. The diagnosis and treatment of envenomation in South Africa.  
429 South African Institute for Medical Research; 1996.
- 430 7. Berling I, Isbister GK. Hematologic effects and complications of snake envenoming. Transfus Med Rev.  
431 2015;29(2):82–9.
- 432 8. Kumar A, Gopalakrishnan M, Kuri HR, Bajpayee A, Kothari N, Garg MK. Case Report: Delayed Diffuse  
433 Alveolar Hemorrhage in Echis sochureki Envenoming, Jodhpur, India. Am J Trop Med Hyg [Internet]. 2022 Jan  
434 31 [cited 2023 Aug 18]; Available from: <https://www.ajtmh.org/view/journals/tpmd/aop/article-10.4269-ajtmh.21-1187/article-10.4269-ajtmh.21-1187.xml>
- 436 9. Krishnadas T, Sasidharan PK. SNAKE BITES IN NORTH KERALA, DEMOGRAPHIC PROFILE  
437 AND MEASURES FOR PREVENTION. J Evol Med Dent Sci [Internet]. 2014 Jan 27 [cited 2023 Aug  
438 18];3(4):990–9. Available from:  
439 [https://go.gale.com/ps/i.do?p=AONE&sw=w&issn=22784748&v=2.1&it=r&id=GALE%7CA646117896&sid=](https://go.gale.com/ps/i.do?p=AONE&sw=w&issn=22784748&v=2.1&it=r&id=GALE%7CA646117896&sid=googleScholar&linkaccess=abs)  
440 [googleScholar&linkaccess=abs](https://go.gale.com/ps/i.do?p=AONE&sw=w&issn=22784748&v=2.1&it=r&id=GALE%7CA646117896&sid=googleScholar&linkaccess=abs)
- 441 10. Zengin S, Yilmaz M, Al B, Yildirim C, Yarbil P, Kilic H, et al. Plasma exchange as a complementary  
442 approach to snake bite treatment: an academic emergency department's experiences. Transfus Apher Sci Off J  
443 World Apher Assoc Off J Eur Soc Haemapheresis. 2013 Dec;49(3):494–8.
- 444 11. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020  
445 statement: an updated guideline for reporting systematic reviews. BMJ [Internet]. 2021 Mar 29 [cited 2023 Oct  
446 20];372:n71. Available from: <https://www.bmj.com/content/372/bmj.n71>
- 447 12. Murad MH, Sultan S, Haffar S, Bazerbachi F. Methodological quality and synthesis of case series and  
448 case reports. BMJ Evid-Based Med. 2018 Apr;23(2):60–3.



- 449 13. Yildirim C, Bayraktaroğlu Z, Gunay N, Bozkurt S, Köse A, Yilmaz M. The use of therapeutic  
450 plasmapheresis in the treatment of poisoned and snake bite victims: an academic emergency department's  
451 experiences. *J Clin Apheresis*. 2006 Dec;21(4):219–23.
- 452 14. Arora P, Belwal S, Uniyal B, Saxena S. Plasmapheresis in a case of acute kidney injury with severe  
453 hemolysis and thrombocytopenia due to hematotoxic (Russell's viper) snake bite. *Saudi J Kidney Dis Transplant*.  
454 2020;31(1):276–80.
- 455 15. Mohan G, Guduri PR, Shastry S. Role of therapeutic plasma exchange in snake bite associated  
456 thrombotic microangiopathy-A case report with review of literature. *J Clin Apheresis*. 2019 Aug;34(4):507–9.
- 457 16. Berber I, Korkmaz S, Sarici A, Erkurt MA, Kuku I, Kaya E, et al. Therapeutic plasma exchange for  
458 envenomation: Is it reasonable? *Transfus Apher Sci*. 2021;60(5):103241.
- 459 17. Dineshkumar T, Dhanapriya J, Sakthirajan R, Thirumalvalavan K, Kurien AA, Balasubramaniyan T, et  
460 al. Thrombotic microangiopathy due to Viperidae bite: Two case reports. *Indian J Nephrol*. 2017;27(2):161.
- 461 18. Erkurt MA, Kuku I, Kaya E, Ozgen U, Berber I, Koroglu M, et al. Therapeutic plasma-exchange in  
462 hematologic disease: results from a single center in Eastern Anatolia. *Transfus Apher Sci*. 2013;48(3):335–9.
- 463 19. Rathnayaka RN, Ranathunga PAN, Kularatne SAM, Sugathadasa K. Therapeutic plasma exchange for  
464 venom-induced thrombotic microangiopathy following hump-nosed pit viper (genus: *Hypnale*) bites: a  
465 prospective observational study. *Wilderness Environ Med*. 2022;33(4):386–98.
- 466 20. Isbister GK, Little M, Cull G, McCoubrie D, Lawton P, Szabo F, et al. Thrombotic microangiopathy  
467 from Australian brown snake (*Pseudonaja*) envenoming. *Intern Med J*. 2007 Aug;37(8):523–8.
- 468 21. Rahmani TRI, Nasasra T, Fuchs L, Almog Y, Lurie Y, Galante O. Acute thrombotic microangiopathic  
469 kidney injury due to *Echis coloratus* envenomation. *Clin Toxicol Phila Pa*. 2020 Apr;58(4):284–6.
- 470 22. Obeidat MB, Al-Swailmeen AM, Al-Sarayreh MM, Rahahleh KM. Thrombotic microangiopathy  
471 following Arabian saw-scaled viper (*Echis coloratus*) bite: Case report. *Am J Case Rep*. 2020;21:e922000-1.
- 472 23. Keyler DE. Envenomation by the lowland viper (*Proatheris superciliaris*): severe case profile  
473 documentation. *Toxicon*. 2008;52(8):836–41.
- 474 24. Kornalik F, Vorlová Z. Non-specific therapy of a hemorrhagic diathesis after a bite by a young *Bothrops*  
475 *asper* (barba amarilla): a case report. *Toxicon Off J Int Soc Toxinology*. 1990;28(12):1497–501.

- 476 25. Valenta J, Stach Z, Kolář M. Envenoming after a snakebite from the Northeast African saw-scaled viper  
477 *Echis pyramidum*: prolonged therapy upon failed treatment by antivenom. *Prague Med Rep.* 2011;112(3):226–  
478 35.
- 479 26. Sampley S, Sakhuja V, Bhasin D, Singh K, Singh H. Plasmapheresis for pulmonary hemorrhage  
480 following viperine snakebite: a case report with review of literature. *Indian J Crit Care Med Peer-Rev Off Publ*  
481 *Indian Soc Crit Care Med.* 2020;24(10):986.
- 482 27. Grace M, Jacob KJ, Jayakumar, P. A. Secondary capillary leak syndrome - Plasmapheresis: Is it the  
483 answer? | *International Archives of Integrated Medicine* | EBSCOhost [Internet]. Vol. 2. 2015 [cited 2024 Jun 30].  
484 p. 187. Available from:  
485 <https://openurl.ebsco.com/contentitem/gcd:102145212?sid=ebsco:plink:crawler&id=ebsco:gcd:102145212>
- 486 28. Hameed S, Memon M, Khan S. Guillain-Barre Syndrome Following a Snakebite: A Case Report and  
487 Review of Literature. *Cureus* [Internet]. [cited 2023 Oct 20];11(7):e5278. Available from:  
488 <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6764639/>
- 489 29. Cobcroft RG, Williams A, Cook D, Williams DJ, Masci P. Hemolytic uremic syndrome following taipan  
490 envenomation with response to plasmapheresis. *Pathology (Phila)* [Internet]. 1997 [cited 2023 Oct 20];29(4):399–  
491 402. Available from: <https://linkinghub.elsevier.com/retrieve/pii/S0031302516349893>
- 492 30. Chuang TY, Lin SW, Chan RC. Guillain-Barré syndrome: an unusual complication after snake bite. *Arch*  
493 *Phys Med Rehabil.* 1996 Jul;77(7):729–31.
- 494 31. Withana M, Rodrigo C, Gnanathan A, Gooneratne L. Presumptive thrombotic thrombocytopenic  
495 purpura following a hump-nosed viper (*Hypnale hypnale*) bite: a case report. *J Venom Anim Toxins Trop Dis.*  
496 2014;20(1):1–6.
- 497 32. Mitrakrishnan JY, Bandula CW, Mitrakrishnan CS, Somaratna K, Jeyalakshmy S. Haemolytic uremic  
498 syndrome a hitherto unreported complication of humpnosed viper envenomation. *Indian J Hematol Blood*  
499 *Transfus Off J Indian Soc Hematol Blood Transfus.* 2013 Jun;29(2):116–8.
- 500 33. Rathnayaka RN, Ranathunga PAN, Kularatne SA. Thrombotic microangiopathy, hemolytic uremic  
501 syndrome, and thrombotic thrombocytopenic purpura following hump-nosed pit viper (Genus: *Hypnale*)  
502 envenoming in Sri Lanka. *Wilderness Environ Med.* 2019;30(1):66–78.

- 503 34. Srivastava A, Taly AB, Gupta A, Moin A, Murali T. Guillain-Barré syndrome following snake bite: An  
504 unusual complication. Ann Indian Acad Neurol [Internet]. 2010 [cited 2023 Oct 20];13(1):67–8. Available from:  
505 <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2859593/>
- 506 35. Reddy SP, Phadnis SA, Kumari P, Sharma N, Sethi J, Pannu AK, et al. Thrombotic microangiopathy in  
507 Russel’s viper envenomation. QJM Int J Med. 2022;115(7):486–7.
- 508 36. Cañas CA, Vecino MJ, Posso-Osorio I. Atypical Hemolytic Uremic Syndrome in a Patient With  
509 Bothrops asper Envenomation. Wilderness Environ Med [Internet]. 2022 Mar 1 [cited 2023 Jul 28];33(1):109–  
510 15. Available from: <https://www.sciencedirect.com/science/article/pii/S108060322100168X>
- 511 37. Namal Rathnayaka RMMK, Nishanthi Ranathunga PEA, Kularatne SAM. Thrombotic Microangiopathy  
512 Following Hypnale zara (Hump-Nosed Pit Viper) Envenoming: The First Known Case Report from Sri Lanka.  
513 Wilderness Environ Med [Internet]. 2020 Mar 1 [cited 2023 Jul 28];31(1):71–7. Available from:  
514 <https://www.sciencedirect.com/science/article/pii/S1080603219301619>
- 515 38. GodavarI KSV. Hemolytic Uremic Syndrome-An unusual complication of snake envenomation. Univ J  
516 Med Med Spec. 2016;2(2).
- 517 39. Murthy PR, Ak AK, Karanth S, Kalashetty M. Thrombotic thrombocytopenic purpura in a patient with  
518 snake bite. Indian J Case Rep [Internet]. 2019 Jun 28 [cited 2024 Jun 30];5(3):277–9. Available from:  
519 <https://mansapublishers.com/index.php/ijcr/article/view/1615>
- 520 40. Wijewickrama ES, Gooneratne LV, Gnanathanan A, Gawarammana I, Gunatilake M, Isbister GK.  
521 Thrombotic microangiopathy and acute kidney injury following Sri Lankan Daboia russelii and Hypnale species  
522 envenoming. Clin Toxicol Phila Pa. 2020 Oct;58(10):997–1003.
- 523 41. Janarthanam MJ. Interesting case of AIDP following snake bite. Univ J Med Med Spec. 2016;2(5).
- 524 42. Senthilkumaran S, Miller SW, Williams HF, Thirumalaikolundusubramanian P, Vaiyapuri S, Patel K.  
525 Hirata’s disease (insulin autoimmune syndrome) following envenomation by a common krait. Toxicon Off J Int  
526 Soc Toxinology. 2022 Nov;219:106923.
- 527 43. Priyankara S, Rathnasiri V, Mihiran T, Premawansa G, Isbister GK, Silva A. Mild venom-induced  
528 consumption coagulopathy associated with thrombotic microangiopathy following a juvenile Russell’s viper  
529 (Daboia russelii) envenoming: A case report. Toxicon Off J Int Soc Toxinology. 2022 Jun;212:8–10.

- 530 44. Laothong C, Sitprija V. Decreased parasympathetic activities in Malayan krait (*Bungarus candidus*)  
531 envenoming. *Toxicon Off J Int Soc Toxinology*. 2001 Sep;39(9):1353–7.
- 532 45. Herath N, Wazil A, Kularatne S, Ratnatunga N, Weerakoon K, Badurdeen S, et al. Thrombotic  
533 microangiopathy and acute kidney injury in hump-nosed viper (*Hypnale species*) envenoming: A descriptive study  
534 in Sri Lanka. *Toxicon [Internet]*. 2012 Jul 1 [cited 2023 Jul 28];60(1):61–5. Available from:  
535 <https://www.sciencedirect.com/science/article/pii/S0041010112000876>
- 536 46. Bava D, Kumar PHA, Gupta A, Mandal S, Bajpayee A, Gopalakrishnan M, et al. Redefining the role of  
537 therapeutic plasma exchange in complications of *Echis carinatus* sochureki envenomation refractory to anti-snake  
538 venom: A case series. *Asian J Transfus Sci*. 2023;17(2):295–300.
- 539 47. Elmoqaddem A, Mrani Alaoui N, Cherrad. M. Hmidi T, Choumi F, Nadour K. Plasma Exchange in a  
540 Patient with a Severe Viper Bite. *Saudi J Med Pharm Sci [Internet]*. 2021 Jan 16 [cited 2024 Jun 30];7(1):50–1.  
541 Available from: [https://saudijournals.com/media/articles/SJMPS\\_71\\_50-51.pdf](https://saudijournals.com/media/articles/SJMPS_71_50-51.pdf)
- 542 48. Casamento AJ, Isbister GK. Thrombotic microangiopathy in two tiger snake envenomations. *Anaesth*  
543 *Intensive Care*. 2011;39(6):1124–7.
- 544 49. Chugh KS. Snake-bite-induced acute renal failure in India. *Kidney Int*. 1989 Mar;35(3):891–907.
- 545 50. Bull BS, Rubenberg ML, Dacie JV, Brain MC. Microangiopathic haemolytic anaemia: mechanisms of  
546 red-cell fragmentation: in vitro studies. *Br J Haematol*. 1968 Jun;14(6):643–52.
- 547 51. Malaque CMS, Duayer IF, Santoro ML. Acute kidney injury induced by thrombotic microangiopathy in  
548 two cases of *Bothrops* envenomation. *Clin Toxicol*. 2019;57(3):213–6.
- 549 52. Bucarechi F, Pimenta MMB, Borrasca-Fernandes CF, Prado CC, Capitani EMD, Hyslop S. Thrombotic  
550 microangiopathy following *Bothrops jararaca* snakebite: case report. *Clin Toxicol*. 2019;57(4):294–9.
- 551 53. Okuda D, Nozaki C, Sekiya F, Morita T. Comparative Biochemistry of Disintegrins Isolated from Snake  
552 Venom: Consideration of the Taxonomy and Geographical Distribution of Snakes in the Genus *Echis*1. *J Biochem*  
553 (Tokyo) [Internet]. 2001 Apr 1 [cited 2023 Oct 20];129(4):615–20. Available from:  
554 <https://doi.org/10.1093/oxfordjournals.jbchem.a002898>

- 555 54. Moschcowitz E. An acute febrile pleiochromic anemia with hyaline thrombosis of the terminal arterioles  
556 and capillaries: an undescribed disease. Arch Intern Med [Internet]. 1925 Jul 1 [cited 2023 Oct 20];36(1):89–93.  
557 Available from: <https://doi.org/10.1001/archinte.1925.00120130092009>
- 558 55. Clark WF. Thrombotic Microangiopathy: Current Knowledge and Outcomes With Plasma Exchange.  
559 Semin Dial [Internet]. 2012 Mar [cited 2023 Oct 20];25(2):214–9. Available from:  
560 <https://onlinelibrary.wiley.com/doi/10.1111/j.1525-139X.2011.01035.x>
- 561 56. Neil J, Choumet V, Le Coupanec A, d'Alayer J, Demeret S, Musset L. Guillain-Barre syndrome: first  
562 description of a snake envenomation aetiology. J Neuroimmunol. 2012 Jan 18;242(1–2):72–7.
- 563 57. Aneja: Idiopathic systemic capillary leak syndrome - Google Scholar [Internet]. [cited 2024 Jun 30].  
564 Available from:  
565 [https://scholar.google.com/scholar\\_lookup?journal=UpToDate&title=Idiopathic+systemic+capillary+leak+synd](https://scholar.google.com/scholar_lookup?journal=UpToDate&title=Idiopathic+systemic+capillary+leak+syndrome&author=R+Aneja&author=S+Manaker&author=G+Finlay&)  
566 [rome&author=R+Aneja&author=S+Manaker&author=G+Finlay&](https://scholar.google.com/scholar_lookup?journal=UpToDate&title=Idiopathic+systemic+capillary+leak+syndrome&author=R+Aneja&author=S+Manaker&author=G+Finlay&)
- 567 58. Udayabhaskaran V, Arun Thomas ET, Shaji B. Capillary Leak Syndrome Following Snakebite  
568 Envenomation. Indian J Crit Care Med [Internet]. 2017 Oct;21(10):698–702. Available from: [https://search-](https://search-ebscohost-com.elibraryaiimsrishikesh.remotexts.in/login.aspx?direct=true&db=ccm&AN=125851540&site=ehost-live)  
569 [ebscohost-](https://search-ebscohost-com.elibraryaiimsrishikesh.remotexts.in/login.aspx?direct=true&db=ccm&AN=125851540&site=ehost-live)  
570 [com.elibraryaiimsrishikesh.remotexts.in/login.aspx?direct=true&db=ccm&AN=125851540&site=ehost-live](https://search-ebscohost-com.elibraryaiimsrishikesh.remotexts.in/login.aspx?direct=true&db=ccm&AN=125851540&site=ehost-live)
- 571 59. Adamski J. Thrombotic microangiopathy and indications for therapeutic plasma exchange. Hematology  
572 [Internet]. 2014 Dec 5 [cited 2023 Oct 20];2014(1):444–9. Available from:  
573 [https://ashpublications.org/hematology/article/2014/1/444/20443/Thrombotic-microangiopathy-and-indications-](https://ashpublications.org/hematology/article/2014/1/444/20443/Thrombotic-microangiopathy-and-indications-for)  
574 [for](https://ashpublications.org/hematology/article/2014/1/444/20443/Thrombotic-microangiopathy-and-indications-for)
- 575 60. Schwartz J, Padmanabhan A, Aqui N, Balogun RA, Connelly-Smith L, Delaney M, et al. Guidelines on  
576 the Use of Therapeutic Apheresis in Clinical Practice-Evidence-Based Approach from the Writing Committee of  
577 the American Society for Apheresis: The Seventh Special Issue. J Clin Apheresis. 2016 Jun;31(3):149–62.
- 578 61. Kaplan AA. Therapeutic plasma exchange: core curriculum 2008. Am J Kidney Dis Off J Natl Kidney  
579 Found. 2008 Dec;52(6):1180–96.
- 580 62. Mokrzycki MH, Kaplan AA. Therapeutic plasma exchange: complications and management. Am J  
581 Kidney Dis Off J Natl Kidney Found. 1994 Jun;23(6):817–27.

582 63. Szczepiorkowski ZM, Winters JL, Bandarenko N, Kim HC, Linenberger ML, Marques MB, et al.  
583 Guidelines on the use of therapeutic apheresis in clinical practice--evidence-based approach from the Apheresis  
584 Applications Committee of the American Society for Apheresis. J Clin Apheresis. 2010;25(3):83–177.

585

586

587

588

589